Abstract 1367: Relationship between exposure and safety/efficacy of loncastuximab tesirine (Lonca) in B-cell non-Hodgkin lymphoma (B-NHL)

Brian Hess(Washington University in St. Louis), Joseph Boni(Adc Therapeutics (Switzerland)), Sam Liao, David Ungar, William Townsend(University College Hospital), Lori Liao, Xiaoyan Zhang(Fujian Medical University), Weiyun Z. Ai(City College of San Francisco)

Cancer Research

July 1, 2021

10.1158/1538-7445.am2021-1367

Cited by 0

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

|Journal of Clinical Oncology|2010|487

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

|The Lancet Oncology|2021|428

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection

|Proceedings of the National Academy of Sciences|2013|287